Cumberland Pharmaceuticals reports Phase 2a ifetroban trial shows safety but no clear efficacy
Cumberland Pharmaceuticals announced top‑line results from its 12‑month Phase 2a ASSIST‑SSc trial of oral ifetroban in systemic sclerosis patients. The drug was generally well tolerated, with mostly mild adverse events, but the small study (31 treated and 10 placebo participants) was not powered to assess efficacy and showed no clear benefit over placebo. The company will submit a clinical study report to the FDA and continue biomarker and cardiac imaging follow‑up studies.
Why it matters
The lack of efficacy data removed a near‑term catalyst for the company, causing the stock to fall about 10‑11% in after‑hours trading. Investors will have to wait for additional studies before any impact on the company's valuation can be reassessed.
Key facts
- 1The trial lasted 12 months. prnewswire.com
- 231 subjects received ifetroban and 10 subjects received placebo. prnewswire.com
- 3Ifetroban was generally well tolerated with mostly mild adverse events. prnewswire.com
- 4Cumberland plans to submit the clinical study report to the FDA and conduct follow‑up biomarker and cardiac imaging studies. prnewswire.com
- 5Shares fell 10.6% in after‑hours trading. investing.com
- 6The stock traded at $7.59 after‑hours. investing.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.